ReVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases, recently announced that it has signed an exclusive license agreement with Cornell University (“Cornell”) for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic disorder that affects central vision (US Patent No. 10,463,687). There are no current treatment options for Stargardt disease, which often manifests in childhood and leads to legal blindness within the second or third decade of life. reVision has assembled a team with proven expertise and passion for advancing life-changing eye therapies.
REV-0100 is a therapy for patients with Stargardt disease that is designed to bind and clear a toxic lipid called lipofuscin that leads to cell death and retinal degeneration. As such, REV-0100 has the potential to reduce lipofuscin levels in the retina. There are no other known products in development that remove accumulated lipofuscin through this mechanism of action and no other approved treatment for Stargardt disease.
On the 8th October Betadex Sulfobutyl Ether Sodium (SBECD) got listed at FDA’s homepage as a drug with orphan drug designation status for the treatment of Stargardt disease.